filmov
tv
Frontline Treatments in ALK-Rearranged NSCLC
Показать описание
Mohammad Jahanzeb, MD, reviews a patient case, evaluates the use of alectinib as a frontline treatment option, and discusses the initial response to therapy.
Targeted Oncology
targeted oncology
oncology
cancer
Рекомендации по теме
0:02:04
Frontline Treatments in ALK-Rearranged NSCLC
0:08:15
ALEX Trial: Frontline Therapy for ALK-Rearranged NSCLC
0:01:17
Dr. Xia on the Frontline Treatment Landscape of ALK-Positive NSCLC
0:03:13
Available Therapies for ALK-Rearranged NSCLC
0:04:37
Treatment of Newly Diagnosed ALK-Rearranged NSCLC
0:01:22
Dr. Liu on Navigating the Frontline Treatment of ALK+ NSCLC
0:01:34
Second-Line Treatments in ALK-Rearranged NSCLC
0:45:52
Targeting ALK - From Discovery to Frontline Treatment
0:06:51
Progression in ALK+ NSCLC After Frontline Therapy
0:08:30
Managing CNS Disease in ALK-Rearranged NSCLC
0:06:28
New Standard of Care for ALK-Rearranged NSCLC
0:08:56
Sequencing Therapies in ALK-Rearranged NSCLC
0:00:55
Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC
0:03:08
Available Treatment Options for Relapsed ALK-Rearranged NSCLC
0:04:43
Upfront Therapy for ALK/ROS1-Rearranged NSCLC
0:03:55
Treatment Considerations in ALK/ROS-1–Rearranged NSCLC
0:05:30
Sequencing Therapy in ALK/ROS1-Rearranged NSCLC
0:03:04
Management of frontline ALK+ NSCLC: brigatinib vs. alectinib
0:05:31
FDA Approval: Frontline Ceritinib for ALK+ NSCLC
0:00:58
Exploring Treatment Options for Patients with ALK-Mutated Lung Cancer
0:03:26
A Case of ALK-Rearranged Non–Small Cell Lung Cancer
0:02:49
Case Presentation: ALK-Rearranged Metastatic NSCLC
0:01:12
Dr Riess on Treatment Developments in ALK+ and ROS1+ NSCLC
0:03:31
ALK/ROS1-Rearranged NSCLC: Approaching Therapy
0:02:04
0:08:15
0:01:17
0:03:13
0:04:37
0:01:22
0:01:34
0:45:52
0:06:51
0:08:30
0:06:28
0:08:56
0:00:55
0:03:08
0:04:43
0:03:55
0:05:30
0:03:04
0:05:31
0:00:58
0:03:26
0:02:49
0:01:12
0:03:31